Biologics CDMO Secondary Packaging Market: Size, Share, Growth and Forecast (2025–2034)

The Biologics CDMO Secondary Packaging Market is experiencing consistent expansion as pharmaceutical companies increasingly rely on contract development and manufacturing organizations (CDMOs) for specialized secondary packaging services. Secondary packaging plays a vital role in ensuring product integrity, regulatory compliance, serialization, labeling, cartoning, and protective packaging for biologic products. With the growing production of biologics such as monoclonal antibodies, vaccines, biosimilars, and gene therapies, demand for reliable packaging solutions continues to increase. The market was valued at approximately USD 5.6 billion in 2025 and is projected to maintain steady growth through 2034.

Request Sample Link:
https://packagingmarketinsights.com/report/biologics-cdmo-secondary-packaging-market/request-sample

Market Overview

The Biologics CDMO Secondary Packaging Market is witnessing sustained growth due to the increasing outsourcing of packaging operations by pharmaceutical manufacturers. As biologic therapies become more complex, specialized packaging solutions have become essential to preserve product quality throughout storage and distribution.

CDMOs provide expertise in serialization, labeling, protective packaging, and regulatory compliance, allowing pharmaceutical companies to improve operational efficiency while focusing on research and product development. The growing biologics pipeline and rising demand for biosimilars are further strengthening the need for advanced secondary packaging services.

Another notable trend is the adoption of smart packaging technologies, including RFID, serialization, and track-and-trace systems, which improve supply chain visibility and help prevent counterfeiting. At the same time, sustainability initiatives are encouraging the use of recyclable and biodegradable packaging materials without compromising product protection.

Market Size and Forecast

The Biologics CDMO Secondary Packaging Market was valued at USD 5.6 billion in 2025 and is estimated to reach USD 6.1 billion in 2026. The market is projected to grow to approximately USD 10.9 billion by 2034, registering a CAGR of 7.5% during the forecast period.

Growth is primarily supported by expanding biologics manufacturing, increasing outsourcing activities, and the need for packaging solutions that meet evolving regulatory standards. Continued investment in advanced packaging technologies is also expected to contribute to long-term market expansion.

Market Drivers

One of the primary drivers of the Biologics CDMO Secondary Packaging Market is the rapid expansion of biologics and biosimilars production. These therapies require highly specialized packaging that maintains product stability while complying with regulatory requirements. As pharmaceutical companies continue expanding biologics development, CDMOs are becoming increasingly important partners for packaging operations.

Another significant growth factor is the increasing outsourcing of secondary packaging. Pharmaceutical companies are leveraging CDMOs to reduce operational costs, improve packaging efficiency, and access specialized infrastructure. Outsourcing also enables manufacturers to focus on research, development, and commercialization while relying on experienced packaging providers.

The growing adoption of smart packaging solutions further supports market growth by enhancing traceability, product authentication, and supply chain transparency.

Market Challenges

Despite positive growth prospects, the market faces challenges associated with stringent regulatory requirements. Compliance with international packaging standards requires continuous investment in advanced technologies, serialization systems, and quality management infrastructure.

Frequent regulatory updates also require CDMOs to adapt their packaging processes to maintain compliance. Smaller organizations may find these investments challenging, potentially limiting the adoption of advanced packaging technologies and increasing operational complexity.

Market Opportunities

The growing focus on personalized medicine presents significant opportunities for the Biologics CDMO Secondary Packaging Market. Customized therapies often require flexible packaging solutions capable of handling small production batches while maintaining strict quality standards. CDMOs are well-positioned to support these specialized packaging requirements.

Emerging markets also represent substantial growth opportunities. Expanding pharmaceutical manufacturing capabilities across Asia Pacific, Latin America, and the Middle East are increasing demand for outsourced secondary packaging services. Improvements in healthcare infrastructure and pharmaceutical production continue to create favorable conditions for market expansion.

Market Segmentation

By Type

Cartons accounted for the largest market share of approximately 31.4% due to their versatility, cost-effectiveness, and suitability for packaging biologic products such as syringes and vials. Advances in labeling and printing technologies continue to improve their regulatory compliance capabilities.

Smart packaging is projected to record the fastest growth, registering a CAGR of 8.2% throughout the forecast period. RFID-enabled solutions and sensor-based technologies are increasingly adopted to improve traceability and product monitoring.

By Material

Plastic remained the leading material segment with a 48.9% market share, supported by its durability, flexibility, and protective characteristics during transportation and storage.

Paper-based packaging is expected to grow at a 7.1% CAGR as pharmaceutical companies increasingly adopt recyclable and biodegradable packaging materials to support sustainability initiatives.

By End-Use

Biopharmaceutical applications dominated the market with a 52.6% share due to increasing production of biologic medicines requiring specialized packaging.

Cell and gene therapy packaging is anticipated to experience the highest growth with a CAGR of 8.5%, driven by rising adoption of advanced therapeutic treatments requiring highly specialized packaging solutions.

Regional Analysis

Asia Pacific

Asia Pacific held the largest market share of 36.8% in 2025 and is expected to maintain strong growth throughout the forecast period. Rapid pharmaceutical manufacturing expansion and increasing contract manufacturing activities continue to support demand for secondary packaging services. China remains the leading contributor due to its extensive manufacturing capacity.

North America

North America represented approximately 34.2% of the market in 2025 and is projected to grow at a 7.2% CAGR. The United States remains the dominant country, supported by strong pharmaceutical research, biologics production, and significant investment in advanced packaging technologies.

Europe

Europe accounted for around 27.6% of the global market in 2025. Germany leads regional demand through its established pharmaceutical manufacturing sector and increasing adoption of sustainable packaging solutions.

Latin America

Latin America captured approximately 6.0% market share and is projected to record the fastest regional CAGR of 7.8%. Brazil continues to lead the region as pharmaceutical outsourcing activities expand.

Middle East & Africa

The Middle East & Africa accounted for approximately 5.4% of the market in 2025 and is expected to grow at a 6.9% CAGR. Investments in healthcare infrastructure and local pharmaceutical manufacturing continue supporting regional demand.

Key Players

The Biologics CDMO Secondary Packaging Market remains moderately competitive, with companies focusing on technology investments, packaging innovation, and service expansion to strengthen their market positions.

Leading companies include:

1. Catalent Inc.

2. Lonza Group

3. Thermo Fisher Scientific Inc.

4. Recipharm AB

5. PCI Pharma Services

6. Sharp Packaging Services

7. West Pharmaceutical Services

8. Almac Group

Conclusion

The Biologics CDMO Secondary Packaging Market is positioned for steady growth through 2034 as pharmaceutical manufacturers continue expanding biologics production and outsourcing packaging operations to specialized CDMOs. Smart packaging technologies, sustainability initiatives, and increasing biologics demand are expected to remain important contributors to market development.

With market size projected to increase from USD 5.6 billion in 2025 to approximately USD 10.9 billion by 2034, the Biologics CDMO Secondary Packaging Market is expected to benefit from continued innovation, expanding pharmaceutical manufacturing, and growing demand for compliant, efficient, and high-quality secondary packaging solutions.

Report Link:
https://packagingmarketinsights.com/report/biologics-cdmo-secondary-packaging-market